Cates JR, Diehl SJ, Crandell JL, Coyne-Beasley T Intervention effects from a social marketing campaign to promote HPV vaccination in preteen boys. Vaccine. 2014 Jul 16;32(33):4171-8. doi: 10.1016/j.vaccine.2014.05.044. Epub 2014 Jun 2.
Cates JR, Shafer A, Diehl SJ, Deal AM Evaluating a County-Sponsored Social Marketing Campaign to Increase Mothers' Initiation of HPV Vaccine for their Pre-teen Daughters in a Primarily Rural Area. Soc Mar Q. 2011 Spring;17(1):4-26.
Centers for Disease Control and Prevention (CDC) National and state vaccination coverage among adolescents aged 13-17 years--United States, 2011. MMWR Morb Mortal Wkly Rep. 2012 Aug 31;61(34):671-7. Erratum in: MMWR Morb Mortal Wkly Rep. 2012 Oct 19;61(41):844.
Coyne CA, Demian-Popescu C, Friend D Social and cultural factors influencing health in southern West Virginia: a qualitative study. Prev Chronic Dis. 2006 Oct;3(4):A124. Epub 2006 Sep 15.
Dietrich AJ, Woodruff CB, Carney PA Changing office routines to enhance preventive care. The preventive GAPS approach. Arch Fam Med. 1994 Feb;3(2):176-83.
Elnicki DM, Morris DK, Shockcor WT Patient-perceived barriers to preventive health care among indigent, rural Appalachian patients. Arch Intern Med. 1995 Feb 27;155(4):421-4.
Fagnan LJ, Dorr DA, Davis M, McGinnis P, Mahler J, King MM, Michaels L Turning on the care coordination switch in rural primary care: voices from the practices--clinician champions, clinician partners, administrators, and nurse care managers. J Ambul Care Manage. 2011 Jul-Sep;34(3):304-18. doi: 10.1097/JAC.0b013e31821c63ee.
Fagnan LJ, Shipman SA, Gaudino JA, Mahler J, Sussman AL, Holub J To give or not to give: Approaches to early childhood immunization delivery in Oregon rural primary care practices. J Rural Health. 2011 Winter;27(4):385-93. doi: 10.1111/j.1748-0361.2010.00356.x. Epub 2011 Jan 11.
Ferrer HB, Trotter C, Hickman M, Audrey S Barriers and facilitators to HPV vaccination of young women in high-income countries: a qualitative systematic review and evidence synthesis. BMC Public Health. 2014 Jul 9;14:700. doi: 10.1186/1471-2458-14-700. Review.
Hughes CC, Jones AL, Feemster KA, Fiks AG HPV vaccine decision making in pediatric primary care: a semi-structured interview study. BMC Pediatr. 2011 Aug 30;11:74. doi: 10.1186/1471-2431-11-74.
Katz ML, Reiter PL, Heaner S, Ruffin MT, Post DM, Paskett ED Acceptance of the HPV vaccine among women, parents, community leaders, and healthcare providers in Ohio Appalachia. Vaccine. 2009 Jun 19;27(30):3945-52. doi: 10.1016/j.vaccine.2009.04.040. Epub 2009 May 3.
Keating KM, Brewer NT, Gottlieb SL, Liddon N, Ludema C, Smith JS Potential barriers to HPV vaccine provision among medical practices in an area with high rates of cervical cancer. J Adolesc Health. 2008 Oct;43(4 Suppl):S61-7. doi: 10.1016/j.jadohealth.2008.06.015.
Koutsky L The epidemiology behind the HPV vaccine discovery. Ann Epidemiol. 2009 Apr;19(4):239-44. doi: 10.1016/j.annepidem.2009.01.023. Review.
Lowy DR, Schiller JT Reducing HPV-associated cancer globally. Cancer Prev Res (Phila). 2012 Jan;5(1):18-23. doi: 10.1158/1940-6207.CAPR-11-0542. Review.
Lyttle NL, Stadelman K Assessing awareness and knowledge of breast and cervical cancer among Appalachian women. Prev Chronic Dis. 2006 Oct;3(4):A125. Epub 2006 Sep 15.
Marlow LA, Waller J, Wardle J Parental attitudes to pre-pubertal HPV vaccination. Vaccine. 2007 Mar 1;25(11):1945-52. Epub 2007 Jan 22.
McElligott JT, Darden PM Are patient-held vaccination records associated with improved vaccination coverage rates? Pediatrics. 2010 Mar;125(3):e467-72. doi: 10.1542/peds.2009-0835. Epub 2010 Feb 15.
McPhee SJ, Detmer WM Office-based interventions to improve delivery of cancer prevention services by primary care physicians. Cancer. 1993 Aug 1;72(3 Suppl):1100-12. Review.
Meites E, Kempe A, Markowitz LE Use of a 2-Dose Schedule for Human Papillomavirus Vaccination - Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2016 Dec 16;65(49):1405-1408. doi: 10.15585/mmwr.mm6549a5.
Mennito SH, Darden PM Impact of practice policies on pediatric immunization rates. J Pediatr. 2010 Apr;156(4):618-22. doi: 10.1016/j.jpeds.2009.10.046. Epub 2010 Jan 13.
Moss JL, Gilkey MB, Rimer BK, Brewer NT Disparities in collaborative patient-provider communication about human papillomavirus (HPV) vaccination. Hum Vaccin Immunother. 2016 Jun 2;12(6):1476-83. doi: 10.1080/21645515.2015.1128601. Epub 2016 Jan 19.
Niccolai LM, Hansen CE Practice- and Community-Based Interventions to Increase Human Papillomavirus Vaccine Coverage: A Systematic Review. JAMA Pediatr. 2015 Jul;169(7):686-92. doi: 10.1001/jamapediatrics.2015.0310. Review.
Pope CA, Escobar-Gomez M, Davis BH, Roberts JR, O'Brien ES, Hinton E, Darden PM The challenge of tetradic relationships in medically interpreted pediatric primary care visits: A descriptive study of communication practices. Patient Educ Couns. 2016 Apr;99(4):542-548. doi: 10.1016/j.pec.2015.10.032. Epub 2015 Dec 8.
Thomas T, Blumling A, Delaney A The Influence of Religiosity and Spirituality on Rural Parents' Health Decision Making and Human Papillomavirus Vaccine Choices. ANS Adv Nurs Sci. 2015 Oct-Dec;38(4):E1-E12. doi: 10.1097/ANS.0000000000000094.
Westfall JM, Mold J, Fagnan L Practice-based research--"Blue Highways" on the NIH roadmap. JAMA. 2007 Jan 24;297(4):403-6.
Increasing Human Papillomavirus (HPV) Immunization Rates: The Rural Adolescent Vaccine Enterprise (RAVE)
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.